Wockhardt Q1 FY25 revenue up 14%
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Subscribe To Our Newsletter & Stay Updated